If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
452.00    7.30 (1.64%)
Bid:
454.60
Ask:
454.80
Spread: 0.20 (0.044%)
Market Cap: £11.37b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Directorate Change

25 Nov 2024 07:00

RNS Number : 4179N
Rentokil Initial PLC
25 November 2024
 

 

Directorate Change: Rentokil Initial plc appoints Paul Edgecliffe-Johnson as new Chief Financial Officer. Current CFO Stuart Ingall-Tombs to retire.

 

Rentokil Initial plc (FTSE: RTO, "the Company") today announces that Paul Edgecliffe-Johnson will join the Board as Chief Financial Officer on 1 January 2025, succeeding Stuart Ingall-Tombs, who is retiring and will step down from the Board on 31 December 2024 after 17 years with the Company, most recently as Chief Financial Officer for 4 years.

 

Paul Edgecliffe-Johnson brings 25 years' experience in finance and international businesses, having most recently been CFO and a member of the Board at Flutter Entertainment PLC. Prior to that he was CFO, Group Head of Strategy, and member of the Board and Executive Committee at InterContinental Hotels Group PLC ("IHG"). Before joining IHG in 2004, Paul was an Associate Director, Corporate Finance at HSBC Holdings PLC.

 

Paul will join the Company on 1 December 2024 as CFO Designate as part of the transition process. Following 1 January 2025, Stuart will continue to be available to support a smooth handover to Paul, including assisting with the completion of the Company's financial statements for the year ending 31 December 2024.

 

Richard Solomons, Chair, said:

 

"We are delighted to announce the appointment of Paul as the Company's new Chief Financial Officer. After a robust selection process, we are confident that he possesses the right skills and experience needed to lead our financial operations and deliver business success. He is a seasoned financial executive with over a decade of company CFO experience, including at IHG where we worked together. Paul has a proven track record of driving profitable growth, optimising financial performance and implementing strategic initiatives.

 

"On behalf of the Board, I would like to thank Stuart for his contributions to Rentokil Initial over many years of committed service and to wish him a happy and healthy retirement."

 

Andy Ransom, Chief Executive, said:

 

"I would like to thank Stuart for his unwavering commitment to Rentokil Initial over the 17 years he has been with the Company. I wish him all the best and hope he has a wonderful time in his retirement.

 

"I am delighted that we have appointed Paul as Chief Financial Officer. He has an exceptional track record and reputation, and I am confident he will make a significant impact in this critical role. I am really looking forward to us working together, as his breadth of experience, along with the insights and guidance he will bring, will be invaluable as we continue to execute our Right Way Strategy in North America and across the rest of the Group."

 

Paul Edgecliffe-Johnson said:

 

"I am excited to join the talented team at Rentokil Initial and to contribute to the growth journey of this global leader. I look forward to leveraging my experience, while maintaining a strong focus on operational excellence, financial discipline and value creation."

 

 

 

Notes:

 

1. Stuart Ingall-Tombs will be treated as a good leaver by reason of his retirement for the purposes of annual bonus and awards under the Deferred Bonus Plan and Performance Share Plan in accordance with the Company's Directors' Remuneration Policy and the relevant plan rules. Further details will be disclosed on the Company's website in due course in compliance with Section 430(2B) of the Companies Act 2006, and details will also be disclosed in the Directors' Remuneration Report within the Company's Annual Report and Accounts for the year ending 31 December 2024.

2. There are no further details to be disclosed relating to Paul Edgecliffe-Johnson under Listing Rule 6.4.8.

 

 

Enquiries:

 

Investors / Analysts: Peter Russell, Rentokil Initial plc: + 44(0)7795166506

Media: Malcolm Padley, Rentokil Initial plc: +44(0)7788978199

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPPGRUGUPCGUC
Date   Source Headline
10th Nov 20232:28 pmRNSDirector/PDMR Shareholding
3rd Nov 20234:26 pmRNSHolding(s) in Company
3rd Nov 20234:22 pmRNSDirector/PDMR Shareholding
1st Nov 202312:50 pmRNSHolding(s) in Company
31st Oct 202311:45 amRNSHolding(s) in Company
30th Oct 20233:03 pmRNSDirector/PDMR Shareholding
30th Oct 202311:55 amRNSCredit rating update
19th Oct 20237:00 amRNSQ3 Trading Update
2nd Oct 202311:35 amRNSBlock listing Interim Review
27th Sep 20232:35 pmRNSDirector/PDMR Shareholding
1st Aug 202312:42 pmRNSDirector/PDMR Shareholding
27th Jul 20237:00 amRNS2023 Interim Results
29th Jun 20239:00 amRNSNotice of Management Presentation
23rd Jun 20235:58 pmRNSDirector/PDMR Shareholding
19th May 20233:03 pmRNSDirector/PDMR Shareholding
12th May 20239:09 amRNSDirector/PDMR Shareholding
11th May 20239:17 amRNSResult of AGM
28th Apr 202310:55 amRNSHolding(s) in Company
21st Apr 20232:41 pmRNSDirector/PDMR Shareholding
20th Apr 20237:00 amRNSQ1 Trading Update
4th Apr 20239:37 amRNSAnnual Financial Report
3rd Apr 202310:08 amRNSBlock listing Interim Review
23rd Mar 20239:42 amRNSDirector/PDMR Shareholding
20th Mar 20234:47 pmRNSDirector/PDMR Shareholding
16th Mar 20237:05 amRNSDirectorate Change
16th Mar 20237:00 amRNSFinal Results
9th Mar 20239:23 amRNSDirector Declaration
27th Feb 20238:55 amRNSNotice of Management Presentation
9th Nov 20224:33 pmRNSDirector Declaration
1st Nov 20222:25 pmRNSCorrection: Q3 Trading Update
1st Nov 20227:00 amRNSQ3 Trading Update
31st Oct 20224:03 pmRNSTotal Voting Rights
24th Oct 20225:15 pmRNSHolding(s) in Company
21st Oct 20224:42 pmRNSHolding(s) in Company
20th Oct 202212:35 pmRNSHolding(s) in Company
19th Oct 202211:43 amRNSHolding(s) in Company
18th Oct 20225:22 pmRNSHolding(s) in Company
17th Oct 20226:07 pmRNSHolding(s) in Company
17th Oct 202211:51 amRNSHolding(s) in Company
14th Oct 20224:39 pmRNSHolding(s) in Company
14th Oct 20224:37 pmRNSHolding(s) in Company
14th Oct 20229:30 amRNSAdditional Listing
13th Oct 20225:42 pmRNSHolding(s) in Company
13th Oct 20223:05 pmRNSHolding(s) in Company
12th Oct 20221:53 pmRNSAcquisition of Terminix Completion
10th Oct 20221:57 pmRNSHolding(s) in Company
10th Oct 20221:52 pmRNSHolding(s) in Company
10th Oct 20221:38 pmRNSHolding(s) in Company
7th Oct 20226:10 pmRNSRentokil Initial
6th Oct 20222:23 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.